Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
GALECTIN (NQ: GALT)
3.980 USD  -0.180 (-4.33%)
Official Closing Price  /  Updated: 3:59 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News
Stories about GALECTIN
 
Bio-Wire Equity Surveillance – Closing Bell 5/28/2013
May 28, 2013
Monday, May 29th, 2013 Overview Big pharmaceutical companies moved up at an average of +1.2% today, while medium-sized pharmas/biotechs moved +1.3% (almost exactly the same). We saw twice the upward... Read More
category AMRN , OMTH , MAKO , and 1 more.
from Bio-Wire.Com
Galectin (GALT) Posts Q1 Loss of 22c/Share
May 10, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8327893 for the full story. Read More
from StreetInsider.com News Articles
Bio-Wire Weekly: April 29 – May 3rd, 2013
May 06, 2013
Bio-Wire Weekly: April 29 – May 3rd, 2013 To get this email earlier, sign up for our email list The Newsmakers: 1.) Auxilium Pharmaceuticals (NASDAQ: AUXL) Auxilium Pharma was down about 8% in the last... Read More
category Prime Content , AEGR , REGN , and 5 more.
from Bio-Wire.Com
Galectin Therapeutics Gets A Bid After Promising Results
April 30, 2013
Galectin Therapeutics Gets A Bid After Promising Results Yesterday was a big victory for Newton, Massachusetts-based Galectin Therapeutics (NASDAQ: GALT) following new data that was presented by the... Read More
category LJPC , Brian L/ Wilson , GALT
from Bio-Wire.Com
Unusual 11 Mid-Day Movers 04/29: (OSH) (WRLS) (GALT) Higher; (LAS) (NTE) (GWAY) Lower
April 29, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8285869 for the full story. Read More
from StreetInsider.com News Articles
BBRY, SINA and WRLS added to EPR's Nasdaq Active Stock Watch List
April 29, 2013
from ACCESSWIRE
Galectin (GALT) Issues Encouraging Update on anti-Galectin Drugs on Liver Cirrohsis
April 29, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8284498 for the full story. Read More
from StreetInsider.com News Articles
Benzinga's Small Cap Movers for Tuesday March 5, 2013
March 05, 2013
Below are highlights from Benzinga's daily coverage of small cap securities making big moves: Galectin Therapeutics Shares of Galectin Therapeutics (NASDAQ: GALT ), the Norcross, GA developer of... Read More
category Benzinga , Movers , News , and 9 more.
from Latest Articles from Benzinga.com
Aegis Capital Reiterates Buy Rating on Galectin Therapeutics After FDA Approval
March 05, 2013
Aegis Capital published a report Tuesday on Galectin Therapeutics (NASDAQ: GALT ) that reiterated its Buy rating and $7.00 price target after the receipt of FDA approval. In the report, Aegis Capital... Read More
category Reiteration , Benzinga , Aegis Capital , and 3 more.
from Latest Articles from Benzinga.com
Unusual 11 Mid-Day Movers 02/25: (ENMD) (GALT) (APPY) Higher; (AFFY) (CEDC) (DVAX) Lower
February 25, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8128944 for the full story. Read More
from StreetInsider.com News Articles
Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with University of Georgia
February 19, 2013
Galectin Therapeutics (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today the establishment of a collaborative drug... Read More
category Benzinga , News , GALT
from Latest Articles from Benzinga.com
Galectin Therapeutics Submits IND Application for Treatment of Fatty Liver Disease
January 31, 2013
Galectin Therapeutics (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug... Read More
category Benzinga , News , GALT
from Latest Articles from Benzinga.com
Galectin (GALT) Submites IND for New GR-MD-02 Indication
January 31, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8046786 for the full story. Read More
from StreetInsider.com News Articles
Galectin Therapeutics Publishes Proceeds by ACS on Symposium
January 28, 2013
Galectin Therapeutics (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the American Chemical Society (ACS), as... Read More
category Benzinga , News , FDA , and 1 more.
from Latest Articles from Benzinga.com
Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies
January 22, 2013
Galectin Therapeutics (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of... Read More
category Benzinga , News , GALT
from Latest Articles from Benzinga.com
Galectin Therapeutics (GALT) Receives U.S. Patent NoA on Galectin Inhibitors in Liver Disease
November 26, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7901523 for the full story. Read More
from StreetInsider.com News Articles
Galectin (GALT) Posts Q3 Loss of 19c/Share
November 09, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7863445 for the full story. Read More
from StreetInsider.com News Articles
Galectin (GALT) Reports Q2 Loss of $0.19
August 10, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7651023 for the full story. Read More
from StreetInsider.com News Articles
Unusual 11 Mid-Day Movers 07/25: (RVBD) (INVN) (LL) Higher; (RSH) (NFLX) (IGT) Lower
July 25, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7603733 for the full story. Read More
from StreetInsider.com News Articles
MARKET PULSE-Apple, Motorola, Invensense, TripAdvisor
July 25, 2012
July 25 (Reuters) - Some U.S. stocks on the move on Wednesday: Read More
category companyNews
from Reuters: Company News
MARKET PULSE-Apple, Invensense, Riverbed, Polycom
July 25, 2012
July 25 (Reuters) - Some U.S. stocks on the move on Wednesday: Read More
category companyNews
from Reuters: Company News
Notable Analyst Rating Changes 07/25: (DOLE) (AMGN) (WHR) Upgraded; (AAPL) (TNK) (PM) Downgraded
July 25, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7603210 for the full story. Read More
from StreetInsider.com News Articles
Aegis Capital Starts Galectin Therapeutics (GALT) at Buy
July 25, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7602508 for the full story. Read More
from StreetInsider.com News Articles
Unusual 11 Mid-Day Movers 07/24: (SPRT) (HSTM) (SANM) Higher; (GNTX) (DV) (WBMD) Lower
July 24, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7599982 for the full story. Read More
from StreetInsider.com News Articles
Galectin (GALT) Investors Take Profit Following Pop on GR-MD-02 Patent News Monday
July 24, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7599401 for the full story. Read More
from StreetInsider.com News Articles
Stocks to Watch: JPM, PEET, RIMM & More
July 23, 2012
Take a look at some of Monday's midday movers: Read More
category Investing/Investment Strategy , Investing/Stock Market
from CNBC.com News
Unusual 11 Mid-Day Movers 07/23: (GALT) (NXY) (GEOY) Higher; (ITMN) (WSLA) (PETS) Lower
July 23, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7596453 for the full story. Read More
from StreetInsider.com News Articles
Galectin Theraputics (Nasdaq:GALT): +72% on Patent for Chronic Liver Disease
July 23, 2012
Northern.WI  7/23/2012  (TheStreetBeat)   --   Galectin Theraputics (Nasdaq:GALT): +72% on Patent for Chronic Liver Disease and today this Monday mover which has traded lower since it's top in April... Read More
from Street Beat: Articles
Galectin Theraputics (Nasdaq:GALT): +72% on Patent for Chronic Liver Disease
July 23, 2012
Northern.WI  7/23/2012  (TheStreetBeat)   --   Galectin Theraputics (Nasdaq:GALT): +72% on Patent for Chronic Liver Disease and today this Monday mover which has traded lower since it's top in April... Read More
from Street Beat: Articles
Galectin Theraputics (Nasdaq:GALT): +72% on Patent for Chronic Liver Disease
July 23, 2012
Northern.WI  7/23/2012  (TheStreetBeat)   --   Galectin Theraputics (Nasdaq:GALT): +72% on Patent for Chronic Liver Disease and today this Monday mover which has traded lower since it's top in April... Read More
from Street Beat: Articles
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here